سعر هالافين 1 مجم/2 مل 2026

Eribulin 1 mg/2 ml single vial for intravenous use (Halaven, Eisai; distributed in Egypt by Multipharma), a microtubule-inhibiting antineoplastic.

• Metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for metastatic disease; prior therapy should have included an anthracycline and a taxane (adjuvant or metastatic setting).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common (>=25%) in metastatic breast cancer: neutropenia, anaemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea and constipation.International label, same product · DailyMed (U.S. National Library of Medicine)
• Most common (>=25%) in liposarcoma and leiomyosarcoma: fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain and pyrexia; common grade 3-4 laboratory abnormalities include neutropenia, hypokalaemia and hypocalcaemia.International label, same product · DailyMed (U.S. National Library of Medicine)

• None (no contraindications are listed in the US label).International label, same product · DailyMed (U.S. National Library of Medicine)

• Neutropenia: severe neutropenia and febrile neutropenia occur (fatal in rare cases); monitor blood counts and adjust the dose. Patients with raised transaminases or bilirubin had more grade 4 and febrile neutropenia.International label, same product · DailyMed (U.S. National Library of Medicine)
• Peripheral neuropathy: monitor for signs of neuropathy; manage with dose delay and adjustment.International label, same product · DailyMed (U.S. National Library of Medicine)
• Embryo-fetal toxicity: can cause fetal harm; advise females of reproductive potential of the risk and to use effective contraception.International label, same product · DailyMed (U.S. National Library of Medicine)

• CYP3A4 inhibitors/inducers and P-gp inhibitorsNo clinically meaningful drug interactions are expected: exposure was not changed by ketoconazole (strong CYP3A4/P-gp inhibitor) or rifampin (CYP3A4 inducer). Eribulin does not inhibit or induce major CYP enzymes at clinical concentrations.DailyMed (U.S. National Library of Medicine)

• Based on animal data and mechanism of action, can cause fetal harm; no human pregnancy data. In rats, embryo-fetal toxicity and severe malformations occurred at doses below the recommended human dose.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; advise women not to breastfeed during treatment and for 2 weeks after the final dose.International label, same product · DailyMed (U.S. National Library of Medicine)

• Eribulin: Inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates, causing G2/M cell-cycle block, mitotic spindle disruption and apoptotic cell death.